lab representative inspecting a vile

MANAGEMENT TEAM

Robert Moscato

CEO

Mr. Moscato is a serial pharmaceutical entrepreneur who has amassed his knowledge during more than 20 years in the pharmaceutical industry, including c-suite leadership and commercial roles. He has successfully built companies from the ground to an integrated organization. Mr. Moscato served as the President and Chief Operating Officer of Cerecor, Inc. (NASDAQ: CERC) from November 2017 until March 2018, and he served on the Board of Directors of Cerecor Inc. from November 2017 until May 2018. Mr. Moscato co-founded Zylera Pharmaceuticals, LLC and served as the CEO for over six years until it was acquired by Cerecor, Inc. in November 2017. Prior to that, Mr. Moscato served as Chief Operating Officer of Deston Therapeutics LLC. Mr. Moscato initially built his career in commercial roles of increasing responsibility with GlaxoSmithKline, where he was a member of the brand team that led the launch of Wellbutrin XL – one of the fastest launches in pharmaceutical history. Mr. Moscato earned an A.S. degree in Food and Nutrition from SUNY Farmingdale, a B.S. in Healthcare Management from St. Francis College and an M.B.A. from Iona College.


Erik Emerson

CCO

Mr. Emerson most recently served as the President and Chief Executive Officer of Symplmed Pharmaceuticals, which he had founded in 2013.  He had led Symplmed to the submission, approval and commercial launch of Prestalia®, and to the eventual sale of such assets to Adhera Therapeutics in June 2017. He also spearheaded the development and launch of Symplmed’s DyrctAxess technology, a patented software designed to manage prescription fulfillment and patient monitoring. DyrctAxess has demonstrated a significant impact on patient conversion to treatment, long-term compliance and overall patient retention. Prior to founding Symplmed, Mr. Emerson served as the head of Commercial Development at XOMA from 2010 to 2013; and as Director of Marketing at Gilead Sciences from 2007 to 2010. He began his career at King Pharmaceuticals in sales, sales training and marketing. Mr. Emerson graduated from the University of Oregon with a Bachelor of Arts in Political Science with a specialization in Administration and Organization.


Eric Teague

CFO

Mr. Teague, age 48, is an international finance and business executive who has amassed his knowledge over 20 years in the public accounting, technology, private equity, manufacturing, and real estate industries, including c-suite leadership and finance roles. He has successfully built and sold several companies. Mr. Teague served as the CFO and Board Member of ARCA Technologies, LLC from 2014 until March 2018. Prior to ARCA, Mr. Teague served as a consultant and managing partner for the Raleigh office of TechCXO. Mr. Teague co-founded Wavelength and served as the CEO for over 6 years until it was acquired by Pavlov Media in 2010. After the acquisition, Mr. Teague served as Chief Business Development Officer and Executive Vice President for Pavlov Media until 2011. Prior to that, Mr. Teague founded TeagueRossCapital, LLC, an NC based private equity firm specializing in turnarounds, workouts, and distressed asset investments. Mr. Teague initially built his career in SEC consulting, cross-border M&A, and audit roles of increasing responsibility with PricewaterhouseCoopers, where he was a member of the Global Capital Markets Practice, the Transaction Services Structuring Practice, and the Business Assurance Practice. Mr. Teague earned a Master in Business Administration degree from the University of North Carolina at Chapel Hill and a B.A. in Accounting from North Carolina State University.

 

Scroll Up